Castle Biosciences, Inc. Common Stock, also called Castle Biosciences, is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. Read More The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX. The listed name for CSTL is Castle Biosciences, Inc. Common Stock.